Oncode Scientific

Menu
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Menu

LIQUID10

Liquid biopsy NGS panel targeting 10 actionable genes for mutations & fusions commonly mutated in cancer especially lung & colon cancer to provide treatment options & prognostic indications.

LEARN MORE

LIQUID100

Liquid biopsy NGS panel targeting >100 actionable genes in cancers for mutation, fusion and SNP to provide treatment options & prognostic indications.

LEARN MORE

HOMOLOGOUS
RECOMBINATION
DEFICIENCY
(HRD)

NGS panel to assess the status
of HRD through the detection of BRCA1/2 gene mutation AND determination of the genomic instability.

LEARN MORE

TISSUE
PREMIUM

NGS panel targeting over 100 genes for mutations, fusions, copy number variations, microsatellite instability and PD-L1 (IHC) to provide treatment options & prognostic indications.

LEARN MORE

TISSUE10

FFPE NGS panel targeting 17 actionable genes for
mutations & fusions commonly mutated in cancers to provide treatment options & prognostic indications.

LEARN MORE

CANCER
HEREDITARY

Blood germline NGS panel targeting 31 genes
associated with hereditary cancer predisposition.

LEARN MORE

ONCODEcipher Lung Premium

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in lung cancer to provide treatment options & prognostic indications.

Learn More

ONCODEcipher Breast & Ovarian Premium

FFPE DNA & blood  panel targeting relevant and actionable genes commonly mutated in breast & ovarian cancer to provide treatment options & prognostic indications.

Learn More

ONCODEcipher Breast & Ovarian Liquid Premium

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

Learn More

ONCODEcipher Colon & Endometrial Premium

FFPE DNA & blood panel targeting 67 relevant genetic mutations in colon and endometrial  cancer AND microsatellite instability (MSI) status to provide treatment options & prognostic indications.

Learn More

ONCODEcipher Pancreatic & Prostate Premium

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in pancreatic and prostate cancer to provide treatment options & prognostic indications.

Learn More

ONCODEcipher Tissue Premium

FFPE DNA & blood  panel targeting relevant and actionable genes commonly mutated in cancerous cell tissue  to provide treatment options & prognostic indications. 

Learn More

ONCODEcipher Liquid Premium

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

Learn More

ONCODEcipher Liquid Premium Plus

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients

Learn More

LIQUID 10

PRODUCT DESCRIPTION

Liquid biopsy NGS panel targeting 10 actionable genes for mutations and fusions commonly mutated in cancers to provide treatment options & prognostic indications.

HIGHLIGHTED GENES

EGFR, ALK, ROS1, RET, BRAF, MET, etc.

ALTERATIONS DETECTED

SNVs, InDels, Fusions/Rearrangements.

LIQUID 100

PRODUCT DESCRIPTION

Liquid biopsy NGS panel designed to target a comprehensive set of 100 over genes frequently found mutated in various cancers. This panel accurately identify genetic alterations and provide valuable insights into potential treatment options, prognostic indications, and implications for chemotherapy recommendations.

HIGHLIGHTED GENES

EGFR, ALK, ROS1, RET, BRAF, MET, ERBB2, BRCA1, BRCA2, NTRK1-3, DPYD, CYP2D6, UGT1A1, etc.

ALTERATIONS DETECTED

SNVs, InDels, Fusions/Rearrangements, CNVs, SNPs.

Homologous
Recombination
Deficiency (HRD)

PRODUCT DESCRIPTION

NGS panel to assess the status of HRD through the detection of BRCA1/2 gene mutation AND determination of the genomic instability. HRD status has prognostic and therapeutic implications that are important to identify the magnitude of benefit of PARP inhibitors during treatment planning.

HIGHLIGHTED GENES

BRCA1, BRCA2, and genomic instability (LOH: Loss of heterozygosity, LST: Large-scale state transitions, and TAI: Telomeric-allelic imbalance markers).

NCCN RECOMMENDS HRD TESTING FOR

Ovarian, fallopian tube and primary peritoneal cancers.

TISSUE PREMIUM

PRODUCT DESCRIPTION

This NGS panel is designed to target over 100 genes for mutations, fusions, copy number variations, microsatellite instability and PD-L1 (IHC) to provide treatment options & prognostic indications.

HIGHLIGHTED GENES

EGFR, ALK, ROS1, BRAF, ESR1, PIK3CA, TP53, NTRK1-3, MSI, PD-L1 and etc.

ALTERATIONS DETECTED

SNVs, InDels, MSI, CNVs and PD-L1.

TISSUE 10

PRODUCT DESCRIPTION

FFPE NGS panel targeting 17 actionable genes commonly mutated in cancers to provide treatment options & prognostic indications.

HIGHLIGHTED GENES

EGFR, ALK, ROS1, RET, BRAF, MET, NTRK1-3, STK11, KEAP1 etc.

ALTERATIONS DETECTED

SNVs, InDels, Fusions/Rearrangements.

CANCER HEREDITARY

PRODUCT DESCRIPTION

NGS panel specifically designed to target 31 germline genes known to be associated with hereditary cancer predisposition. This panel detects genetic variations in these genes, enabling the identification and assessment of potential inherited cancer risks in individuals.

HIGHLIGHTED GENES

Germline BRCA1&2, BARD1, PALB2, CHEK2, TP53, MLH1, MSH2, MSH6, PMS2, EPCAM, etc.

ALTERATIONS DETECTED

SNVs, InDels, Large Genomic Rearrangements, Large Deletion/ Duplications and CNVs

ONCODEcipher Lung Premium NGS Panel

Product Description:

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in lung cancer to provide treatment options & prognostic indications.

Highlighted Genes -- EGFR, ALK, ROS1, RET, BRAF, MET, PDL1 etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 15ml Blood in cfDNA tubes
  • FFPE Block or 15 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Breast & Ovarian Premium NGS panel

Product Description:

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in breast & ovarian cancer to provide treatment options & prognostic indications.

Highlighted Genes -- Somatic BRCA1 & BRCA2, ESR1, PIK3CA, TP53, NR-21, NR-24, BAT-25, BAT-26, MONO-27 (immunotherapy), MLH1, MSH2, MSH6 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 3ml Blood in EDTA tubes
  • FFPE Block or 10 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Breast & Ovarian Liquid Premium NGS panel

Product Description:

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

Highlighted Genes -- BRCA1 & BRCA2, ESR1, PIK3CA, TP53, MLH1, MSH2, MSH6 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 15ml Blood in cfDNA tubes (2 tubes)

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Colon & Endometrial Premium NGS Panel

Product Description:

FFPE DNA & blood panel targeting 67 relevant genetic mutations in colon and endometrial cancer AND microsatellite instability (MSI) status to provide treatment options & prognostic indications.

Highlighted Genes -- Mutations of RAS/ RAF/ MEK/ MAP kinase signaling pathway, NR-21, NR-24, BAT-25, BAT-26, MONO-27 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 3ml Blood in 1 EDTA tubes
  • FFPE Block or 10-15 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

15 working days

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Pancreatic & Prostate Premium NGS Panel

Product Description:

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in pancreatic and prostate cancer to provide treatment options & prognostic indications.

Highlighted Genes -- KRAS, TP53, CDKN2A, SMAD4, NTRK1,2,3, NR-21, NR-24, BAT-25, BAT-26, MONO-27, Germline BRCA1,2, MLH1, MSH2, EPCAM and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 3ml Blood in 1 EDTA tubes
  • FFPE Block or 25 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Tissue Premium NGS Panel

Product Description:

FFPE DNA & blood panel targeting relevant and actionable genes commonly mutated in cancerous cell tissue to provide treatment options & prognostic indications.

Highlighted Genes --NTRK1,2,3,PDL-1, ESR1, PIK3CA, TP53, NR-21, NR-24, BAT-25, BAT-26, MONO-27, MLH1, MSH2, MSH6 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 3ml Blood in 1 EDTA tubes
  • FFPE Block or 30 Unstained Slides
  • 1 H&E Stained Slide
  • HPE report

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Liquid Premium NGS Panel

Product Description:

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

Highlighted Genes -- BRCA1 & BRCA2, ESR1, PIK3CA, TP53, NR-21, NR-24, BAT-25, BAT-26, MONO-27, MLH1, MSH2, MSH6 and etc.

Technique:

Next Generation Sequencing (NGS)

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 30ml Blood in cfDNA tubes (4 tubes)

TAT

Turn Around Time:

15 Working Days

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us

ONCODEcipher Liquid Premium Plus NGS Panel

Technique:

Next Generation Sequencing (NGS)

Product Description:

Non-invasive cell free circulating tumor DNA (ctDNA) panel that delivers information on a variety of treatment/prognosis informative mutations in the genes which are known to play a role in solid tumors using only the blood of the patients.

Highlighted Genes -- BRCA1 & BRCA2, ESR1, PIK3CA, TP53, NR-21, NR-24, BAT-25, BAT-26, MONO-27, MLH1, MSH2, MSH6 and etc.

Test Methodology:

Cell free DNA extracted from plasma is subjected to amplification-based library preparation and massively parallel sequencing. Sequencing analysis is performed using commercial bioinformatics pipelines and annotation is done using proprietary and public databases.

Specimen Requirements:

  • 30ml Blood in cfDNA tubes (4 tubes)

TAT

Turn Around Time:

10-15 Working Days
3-4 weeks (For germline results)

shipment_requirement

Shipment Requirement:

Keep specimens at room temperature. DO NOT ship on ice or dry ice or expose to direct sunlight.

Contact Us